VolitionRx Limited logo

VolitionRx LimitedNYSE American: VNRX

Profile

Sector:

Healthcare

Country:

United States

IPO:

02 March 2012

Next earnings report:

15 November 2024

Last dividends:

N/A

Next dividends:

N/A
$53.97 M
-75%vs. 3y high
35%vs. sector
-vs. 3y high
-vs. sector
-105%vs. 3y high
8%vs. sector
-97%vs. 3y high
91%vs. sector

Price

after hours | Fri, 01 Nov 2024 22:28:58 GMT
$0.59+$0.04(+6.55%)

Dividend

No data over the past 3 years
$395.80 K$650.00 K
$395.80 K-$6.99 M

Analysts recommendations

Institutional Ownership

VNRX Latest News

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
prnewswire.com03 October 2024 Sentiment: POSITIVE

HENDERSON, Nev. , Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management.

VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update
prnewswire.com14 August 2024 Sentiment: NEUTRAL

Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering
prnewswire.com09 August 2024 Sentiment: POSITIVE

$7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HENDERSON, Nev. , Aug. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of 12,727,273 shares of its common stock (or common stock equivalents in lieu thereof) and milestone-linked warrants, composed of series A warrants to purchase up to 12,727,273  shares of common stock and series B warrants to purchase up to 12,727,273 shares of common stock, at an offering price of $0.55 per share (or common stock equivalent in lieu thereof) and accompanying warrants.

Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing
prnewswire.com09 July 2024 Sentiment: POSITIVE

HENDERSON, Nev. , July 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed PharmaVentures Ltd ("PharmaVentures"), a leading transaction advisory firm, to provide strategic advice and transactional support on the out-license of Volition's expanding oncology portfolio.

VolitionRx has 'compelling plans' to advance veterinary care in 2024
Proactive Investors04 January 2024 Sentiment: POSITIVE

VolitionRx (NYSE-A:VNRX) has outlined its plans to advance its veterinary diagnostics platform after a successful 2023. Among the notable achievements in the past year, Volition successfully launched the Nu.Q Vet Cancer Test in significant markets through various licensing, supply, and distribution agreements.

Volition secures €5M in financing from Belgium's Wallonie Entreprendre
Proactive Investors05 December 2023 Sentiment: POSITIVE

VolitionRx (NYSE-A:VNRX) told investors it has secured €5 million (roughly $5.5 million) in financing from Belgium's Wallonie Entreprendre (WE) for the ongoing development of its Nu.Q product portfolio. The multi-national epigenetics company said the funds will also be used to advance the clinical and regulatory program for Nu.Q NETs, which it believes will aid the early diagnosis of diseases such as sepsis, as it works with leading clinicians and researchers to help facilitate the effective introduction of the diagnostic solution into clinical practice.

VolitionRx Limited (VNRX) Q3 2023 Earnings Call Transcript
Seeking Alpha15 November 2023 Sentiment: POSITIVE

VolitionRx Limited (NYSE:VNRX ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President, Investor Relations Cameron Reynolds - President and Group Chief Executive Officer Terig Hughes - Group Chief Financial Officer Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary Andrew Retter - Medical Consultant, Volition Louise Batchelor - Chief Marketing and Communications Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Tim Moore - EF Operator Good morning, ladies and gentlemen. Thank you for standing by.

VolitionRx's Nu.Q Vet Cancer Test sees five-fold revenue surge in 2023
Proactive Investors14 November 2023 Sentiment: POSITIVE

VolitionRx (NYSE-A:VNRX) said its Nu.Q Vet Cancer Test revenue has seen a nearly five-fold increase in sales over the first nine months of 2023 compared to the same period last year. The Nu.Q test involves analyzing nucleosomes, which are structural units of DNA, to identify specific patterns or changes associated with the presence of cancer in animals.

VolitionRx joins up with VPG to launch Nu.Q Vet Cancer Test in UK and Ireland
Proactive Investors06 November 2023 Sentiment: POSITIVE

VolitionRx (NYSE-A:VNRX) told investors it has joined forces with Veterinary Pathology Group (VPG) to launch the Nu.Q Vet Cancer Test to veterinary practices in the UK and Ireland. The NuQ Vet Cancer Test is a groundbreaking tool for the early detection and monitoring of cancer in dogs and VPG will be the first-to-market diagnostics laboratory in the UK to offer the test, the company said.

VolitionRx highlights study demonstrating Nu.Q NETs is promising biomarker for septic shock
Proactive Investors19 October 2023 Sentiment: POSITIVE

VolitionRx (NYSE-A:VNRX) has highlighted a recently published paper in Annals of Intensive Care which shows the company's Nu.Q NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and it could play a vital role in sepsis prognosis. The paper is about a 150-patient study led by Professor Guillaume Monneret, Head of Clinical Immunology Laboratory at Hospices Civils de Lyon in France.

What type of business is VolitionRx Limited?

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

What sector is VolitionRx Limited in?

VolitionRx Limited is in the Healthcare sector

What industry is VolitionRx Limited in?

VolitionRx Limited is in the Diagnostics & Research industry

What country is VolitionRx Limited from?

VolitionRx Limited is headquartered in United States

When did VolitionRx Limited go public?

VolitionRx Limited initial public offering (IPO) was on 02 March 2012

What is VolitionRx Limited website?

https://www.volition.com

Is VolitionRx Limited in the S&P 500?

No, VolitionRx Limited is not included in the S&P 500 index

Is VolitionRx Limited in the NASDAQ 100?

No, VolitionRx Limited is not included in the NASDAQ 100 index

Is VolitionRx Limited in the Dow Jones?

No, VolitionRx Limited is not included in the Dow Jones index

When was VolitionRx Limited the previous earnings report?

No data

When does VolitionRx Limited earnings report?

The next expected earnings date for VolitionRx Limited is 15 November 2024